Blueprint Medicines Corp (NASDAQ:BPMC) Director Charles A. Rowland, Jr. sold 11,818 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $95.15, for a total transaction of $1,124,482.70. Following the completion of the transaction, the director now owns 11,818 shares of the company’s stock, valued at approximately $1,124,482.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of BPMC opened at $90.29 on Thursday. Blueprint Medicines Corp has a fifty-two week low of $44.58 and a fifty-two week high of $100.76. The firm has a market capitalization of $4.53 billion, a P/E ratio of -16.75 and a beta of 1.45. The business’s 50-day simple moving average is $84.94. The company has a quick ratio of 6.59, a current ratio of 6.59 and a debt-to-equity ratio of 0.27.
Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.15). Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.38 million. During the same quarter last year, the company posted ($1.29) EPS. Blueprint Medicines’s quarterly revenue was down 23.2% on a year-over-year basis. As a group, sell-side analysts forecast that Blueprint Medicines Corp will post -7.76 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in BPMC. Rhumbline Advisers grew its stake in shares of Blueprint Medicines by 46.1% during the 4th quarter. Rhumbline Advisers now owns 55,349 shares of the biotechnology company’s stock worth $2,984,000 after acquiring an additional 17,475 shares during the period. SG Americas Securities LLC grew its stake in shares of Blueprint Medicines by 485.3% during the 4th quarter. SG Americas Securities LLC now owns 9,962 shares of the biotechnology company’s stock worth $537,000 after acquiring an additional 8,260 shares during the period. Comerica Bank grew its stake in shares of Blueprint Medicines by 20.9% during the 4th quarter. Comerica Bank now owns 12,617 shares of the biotechnology company’s stock worth $878,000 after acquiring an additional 2,180 shares during the period. First Trust Advisors LP bought a new position in shares of Blueprint Medicines during the 4th quarter worth $1,390,000. Finally, Westfield Capital Management Co. LP grew its stake in shares of Blueprint Medicines by 14.4% during the 4th quarter. Westfield Capital Management Co. LP now owns 582,826 shares of the biotechnology company’s stock worth $31,420,000 after acquiring an additional 73,446 shares during the period. Institutional investors and hedge funds own 97.46% of the company’s stock.
BPMC has been the subject of several research analyst reports. BidaskClub downgraded shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 12th. Morgan Stanley started coverage on shares of Blueprint Medicines in a research note on Wednesday, April 3rd. They set an “overweight” rating and a $112.00 target price for the company. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Sunday, June 2nd. ValuEngine upgraded shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 10th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Thursday, May 23rd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $105.83.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
See Also: Trading on Margin
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.